CD40-targeting therapies can enhance the dendritic cell priming of tumor-specific T cells and repolarize intratumoral macrophages to alleviate the tumoral immunosuppressive environment and remodel the extracellular matrix. Mitazalimab is a potent agonistic CD40 monoclonal IgG1 antibody currently under clinical development. This study used RNA sequencing of blood samples from a subset of patients from a Phase I trial with mitazalimab (NCT02829099) to assess peripheral pharmacodynamic activity. We found that mitazalimab induced transient peripheral transcriptomic alterations (at 600 µg/kg and 900 µg/kg dose administered intravenously), which mainly were attributed to immune activation. In particular, the transcriptomic alterations showed a reduction in effector cells (e.g., CD8+ T cells and natural killer cells) and B cells peripherally with the remaining cells (e.g., dendritic cells, monocytes, B cells, and natural killer cells) showing transcription profiles consistent with activation. Lastly, distinct patient subgroups based on the pattern of transcriptomic alterations could be identified. In summary, the data presented herein reinforce the anticipated mode of action of mitazalimab and support its ongoing clinical development.
Supplementary Figure S7 Anti-tumor efficacy of ATOR-4066 at different doses in hCD40tgxC57BL/6 mice. MC38-CEA bearing mice were treated i.p. with ATOR-4066 at multiple doses or vehicle on day 6, 10 and 13 and tumor volume was measured and survival monitored. Group size n = 10 to 20, pooled data from two experiments. Each line represents tumor volume of individual mice.
Supplementary Figure S6 Anti-tumor efficacy of titration of ATOR-4066 dose in MC38-CEA bearing mice. F1 (hCD40tgxC57BL/6) mice were treated i.p. with vehicle, or 0.5 mg/kg (10 ug/mouse), 1 mg/kg (20 ug/mouse), 2 mg/kg (40 ug/mouse), 3 mg/kg (60 ug/mouse), 4 mg/kg (80 ug/mouse), 6.25 mg/kg (125 ug/mouse) or 8.35 mg/kg (167 ug/mouse) of ATOR-4066 on days 6, 10 and 13. Tumors were measured twice a week. Each line represents tumor volume of individual mice. Size n = 10 to 29/group.
Despite recent progress within the field of immuno-oncology, immune suppression in the tumor microenvironment, defective antigen presentation, and low levels of tumor-specific T cells are key limitations of current cancer immunotherapies. CD40-targeting immunotherapies hold promise for addressing these limitations across solid tumors. In this study, we describe ATOR-4066, a bispecific antibody that targets CD40 and CEACAM5, developed using the Neo-X-Prime platform. ATOR-4066 showed potent CEACAM5-dependent activation in vitro, with an ability to activate intratumoral immune cells from patient-derived material. In vivo, ATOR-4066 induced superior antitumor activity compared with a CD40 mAb in MC38–carcinoembryonic antigen tumors and cured mice with well-established tumors with heterogeneous CEACAM5 expression. Using RNA sequencing, flow cytometry, and cytokine analysis, we showed that ATOR-4066 promoted immune cell trafficking to tumors and activated both myeloid cells and T cells within the tumor microenvironment, with limited immune activation in the periphery. ATOR-4066 initially induced a T cell–independent antitumor response, yet we found that a functional T-cell response was critical for long-term tumor control and immunity directed to tumor antigens other than CEACAM5. Finally, we demonstrated that ATOR-4066 synergized with PD-1 blockade in vitro. In conclusion, these data provide mechanistic evidence for the proposed mode of action and support further development of ATOR-4066 in CEACAM5-expressing cancers.
Supplementary Figure S16. The importance of T cells during treatment was evaluated using aCD4 and aCD8 depleting antibodies in F1 hCD40tgxC57BL/6 mice, inoculated with MC38-CEA and treated with ATOR-4066 or vehicle 6, 10 and 13 days after tumor inoculation.
Supplementary Figure S5 B cells were enriched from PBMCs isolated from leucocyte concentrates obtained from healthy donors using B Cell Isolation Kit II, human (Miltenyi, 130-091-151). 50,000 B cells were incubated with IL-4 (10 ng/mL) in 96-well plates together with CHO-CEACAM5 cells (60,000 cells/well), CHO-WT cells (60,000 cells/well), soluble CEACAM5 (s-CEA) or combination of CHO-CEACAM5 and s-CEA, with or without ATOR-4066 (1 nM). After 48 hours, the cells were stained for viability and expression of CD45, CD19 and CD86 and analyzed by flow cytometry. The figure shows percentage of B cells expressing CD86. ATOR-4066 induce activation of B cells in co-cultures of CHO-CEACAM5 cells, but not CHO-WT cells, and this activation is not reduced by addition of s-CEA. Moreover, ATOR-4066 in the sole presence of s-CEA does not activate B cells.